Our company

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Our strategy

Our organisation

Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

BioPharmaceuticals

We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.

Learn more

Oncology

We are leading a revolution in oncology to redefine cancer care. We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.

Learn more

Our purpose and values

Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.

We push the boundaries of science to deliver life-changing medicines.

Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators.

We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.

Our values determine how we work together and the behaviours that are integral to our drive for success. Our values guide our decision making, define our beliefs and foster a strong AstraZeneca culture.

Discover how our Values and behaviours come to life in the work that we do

Our people

Pascal Soriot

Executive Director and Chief Executive Officer

Ezogelin Oflazoglu-Gruyters

Vice-President, Head of External R&D and Strategic Alliances, Oncology R&D

Menelas (Mene) Pangalos

Executive Vice-President, BioPharmaceuticals R&D

Maria Belvisi

Senior Vice President and Head of Research and Early Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D

Helen Angell

Director, Translational Medicine, Oncology Research & Early Development

Paul Harper

Principal Scientist, Discovery Sciences, R&D

Jason Snape

Global Safety, Health and Environment Director and Senior Principal Environmental Scientist

Tonya Villafana

Vice President, Global Franchise Head, Infection
View our people
View our Senior Executive Team
View our board

Sustainability

Access to healthcare

Access to healthcare at AstraZeneca goes beyond our medicines. We provide healthcare solutions along a continuum of care — from prevention, awareness, diagnosis and treatment, to post-treatment and wellness. We work across our main therapy areas to address unmet medical needs and health disparities.

Environmental protection

Climate change is now a climate crisis. The effects of the continued growth of the global economy and its reliance on fossil fuels are putting at risk not only human health, but also the ability of the Earth to sustain life. We are taking action now because we recognise the inextricable link between a healthy planet and healthy people.

Ethics and transparency

We want to be valued for not only our medicines, but also for the way we work. We aim to build trust by demonstrating integrity, transparency and fair treatment in everything that we do. We have committed to ensure racial equity in our workplace and access to our medicines, in our clinical trials and beyond.
See more about Sustainability

Key information

View our pipeline
Annual Report 2020

Partnering brochure

PDF 1,609KB

What science can do

It takes passion, energy and knowledge to enable us to put science at the heart of everything we do. Learn more about our exciting work in stories from our people and partners.

Read more

News & press releases

Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer

  • Corporate Press Release

AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial

  • Corporate Press Release

Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis

  • Corporate Press Release

AZD7442 request for Emergency Use Authorization for COVID-19 prophylaxis filed in US

  • Corporate Press Release

Enhertu granted Breakthrough Therapy Designation in US for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

  • Corporate Press Release

AstraZeneca to fully acquire Caelum Biosciences

  • Corporate Press Release
View all news